Currentmedical mutual - ohioPolicy AHS - F2019 - Flow Cytometry, 1

Flow Cytometry

Defines medical coverage criteria and reimbursement limitations for flow cytometry (immunophenotyping and DNA/cell cycle analysis) including indications covered, not-covered uses, applicable CPT/HCPCS codes, and billing/unit limits. Applies to members of Medical Mutual - Ohio per benefit coverage and government regulations.

Policy Summary

Payermedical mutual - ohio

PolicyFlow Cytometry

Policy CodePolicy AHS - F2019 - Flow Cytometry, 1

Change TypeReviewed and updated (background/guidelines/references)

Effective DateNov 16, 2015

Next Review Date

Key ActionLimit subsequent flow cytometry testing in neoplasms with established immunophenotype to diagnostically relevant markers and document rationale for additional markers.

POLICY UPDATE CHANGES

03/05/2025 Reviewed and Updated: background, guidelines and recommendations, and evidence-based scientific references were updated; literature review did not necessitate modifications to coverage criteria.

10Covered Indications Listed

1Not-Covered Uses

9CPT/HCPCS Codes Referenced

MultipleReferences cited

This policy (Policy Number: AHS - F2019 - Flow Cytometry, 1; Status: CURRENT) defines coverage and reimbursement rules for flow cytometry testing. Flow cytometry is a laboratory technique for live cell analysis that measures optical light scattering and fluorescence to evaluate cellular properties and enumerate cells. Immunophenotyping (flow cytometric identification of cell surface, cytoplasmic, or nuclear markers) is an established, medically necessary use for a range of hematologic and immunologic indications including cytopenias, lymphomas, leukemia, myeloproliferative and lymphoproliferative disorders, myelodysplastic syndromes, B- and T-cell monitoring (including HIV/AIDS), mast cell neoplasms, paroxysmal nocturnal hemoglobinuria, plasma cell disorders, primary immunodeficiencies (PIDs), primary platelet disorders (non-neoplastic), and non-neoplastic red and white cell disorders.

Flow cytometry-derived cell cycle measures such as DNA ploidy (DNA Index) and proliferative activity (S-phase fraction, SPF) are discussed in the policy but are not covered for routine prognostic or therapeutic decision-making in cancer due to inconsistent evidence. Effective date/Initial presentation: 11/16/2015; Last review / Revision Date: 03/05/2025.

Policy summary

Covered Indications Listed10

Explicit Not-Covered UseMeasurement of DNA index or S-phase fraction for prognostic/therapeutic purposes in routine cancer management DOES NOT MEET COVERAGE CRITERIA

CPT/HCPCS Codes Referenced88182, 88184-88189, 86355, 86356, 86357, 86359, 86360, 86361, 86367

References citedMultiple (guidelines and primary studies listed: ASCO, CAP/ASH, NCCN, ERIC/ESCCA, ISTH, and primary literature)

Effective Date2015-11-16

Last Review2025-03-05

Medical-Necessity / Covered Indications

Medically Necessary / Covered Indications

Flow cytometry immunophenotyping of cell surface markers MEETS COVERAGE CRITERIA for any of the following conditions:

Medically Necessary / Covered Indications - list

Individuals with cytopenias, lymphomas, leukemia, myeloproliferative and lymphoproliferative disorders, or myelodysplastic syndrome.
B-cell monitoring for immunosuppressive disorders.
T-cell monitoring for HIV infection and AIDS.
Individuals with mast cell neoplasms.
Individuals with paroxysmal nocturnal hemoglobinuria.
Preoperative or postoperative monitoring of individuals who will undergo or have undergone organ transplantation.
Individuals with plasma cell disorders.
Individuals with primary immunodeficiencies (PIDs).
Individuals with primary platelet disorders (non-neoplastic).
Individuals with red cell and white cell disorders (non-neoplastic).

Reimbursement / Billing Limitations

The following reimbursement limitations will apply for flow cytometry:

Reimbursement / Billing Limitations - rules

Use codes for hematolymphoid neoplasia assessment: For flow cytometric immunophenotyping for the assessment of potential hematolymphoid neoplasia, use codes 88184-88189.
88184 first marker limit: Code 88184 should be used for the first marker, per specimen, and is reimbursable up to a maximum of two units per date of service.
Technical component only; first marker.
88185 additional markers limit: Code 88185 should be used for each additional marker and is reimbursable up to a maximum of 35 units, per date of service.
Limit subsequent testing for established immunophenotype: In patients with a neoplasm with an established immunophenotype, subsequent tests for that neoplasm should be limited to diagnostically relevant markers.
Do not combine 88187-88189: Codes 88187, 88188, and 88189 should not be used together for a single specimen in any combination.
88187-88189 unit limits: Codes 88187, 88188, and 88189 are reimbursed at one unit per specimen, up to two specimens, per date of service.
Do not combine interpretation with enumeration codes: Codes 88187-88189 should not be used in conjunction with codes 86355, 86356, 86357, 86359, 86360, 86361, 86367.
Use enumeration codes as single units: Use codes 86355, 86357, 86359, 86360, 86361, or 86367 for cell enumeration. These codes are reimbursable as single units only.

Flow cytometry immunophenotyping / interpretation / cell cycle codes (referenced for use and reimbursement limits)CPTCovered

88182	Flow cytometry, cell cycle or DNA analysis.
88184	Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; first marker.
88185	Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker.
88187	Flow cytometry, interpretation; 2 to 8 markers.
88188	Flow cytometry, interpretation; 9 to 15 markers.
88189	Flow cytometry, interpretation; 16 or more markers.

Cell enumeration codes (for cell counts)CPTCovered

86355	B cells, total count.
86356	Mononuclear cell antigen, quantitative (eg, flow cytometry), not otherwise specified, each antigen.
86357	Natural killer (NK) cells, total count.
86359	T cells; total count.
86360	T cells; absolute CD4 and CD8 count, including ratio.
86361	T cells; absolute CD4 count.
86367	Stem cells (ie, CD34), total count.

Provider Actions & Billing Rules

Billing Rule

Use specified codes and unit limits

Report immunophenotyping using listed CPT codes and follow the specified unit and combination limits when billing. Do not report interpretation codes 88187-88189 together for a single specimen or in conjunction with the listed cell enumeration codes.

88184 — first marker, technical component only; reimbursable up to 2 units per date of service
88185 — each additional marker, technical component only; reimbursable up to 35 units per date of service
88187 — interpretation; 2–8 markers; reimbursed 1 unit per specimen, up to 2 specimens per date of service
88188 — interpretation; 9–15 markers; reimbursed 1 unit per specimen, up to 2 specimens per date of service
88189 — interpretation; 16+ markers; reimbursed 1 unit per specimen, up to 2 specimens per date of service
Do not use codes 88187, 88188, and 88189 together for a single specimen in any combination
Do not report codes 88187-88189 in conjunction with cell enumeration codes 86355, 86356, 86357, 86359, 86360, 86361, 86367
Use cell enumeration codes (86355, 86357, 86359, 86360, 86361, 86367) as single units only

Documentation Required

Limit subsequent testing in established neoplasm

For neoplasms with an established immunophenotype, limit subsequent flow cytometry testing to diagnostically relevant markers. If testing beyond the established immunophenotype is performed, document the clinical rationale for the additional markers in the medical record.

Documentation Required

Reference verification requirement

This policy is subject to change; always verify and reference the most current official document at the publisher URL because printed copies may be outdated.

Background & Evidence Summary

Flow cytometry is a laboratory technique that measures optical and fluorescence characteristics of single cells or particles to determine size, granularity, viability, and marker expression. Typical instruments use lasers, optics, detectors, and computer analysis; fluorescent reagents (for example, DNA-binding dyes and fluorescently conjugated antibodies) enable detection of DNA content, cell cycle phases, and immunophenotypic markers. Immunophenotyping—identifying immune cell markers and subsets—is the most common clinical application and is widely used for diagnostic and monitoring purposes (for example in transplantation, hematologic malignancies, and primary or secondary immunodeficiencies). Guideline groups (eg, Bethesda Consensus, CAP/ASH, ERIC/ESCCA, NCCN, ISTH) endorse flow cytometric immunophenotyping in specified clinical settings and for initial diagnostic workups and monitoring.

By contrast, flow cytometry assessment of DNA content (DNA Index/ploidy) and S-phase fraction (SPF) estimates cell proliferative activity and have been evaluated as potential prognostic markers in multiple cancers. However, multiple guidelines and evidence reviews note inconsistent or insufficient data to support routine clinical use for prognostication (for example ASCO tumor marker guidance and NCCN guidance do not recommend S-phase fraction or DNA ploidy as routine management tools), and this policy explicitly states that measurement of DNA Index or SPF for routine prognostic or therapeutic purposes in cancers does not meet coverage criteria.

Evidence highlights

Policy Evidence SummaryMultiple society guidelines and primary studies support immunophenotyping utility; evidence for DNA ploidy/SPF prognostic use is inconsistent

Key guideline citationsASCO tumor marker recommendations (2006/2007), CAP/ASH initial diagnostic workup of acute leukemia (2017), NCCN guidelines, ERIC/ESCCA, ISTH

Recent literature examplesPrimary immunodeficiency utility (Abraham RS 2016); mass cytometry commentary (Cosma A 2017); MRD multiparameter flow cytometry in AML (Wang Z 2019)

Term	Definition
SPF	S-phase fraction; assessment of percentage of cells actively synthesizing DNA.
DNA Index	Flow cytometry-derived DNA content (ploidy).
FCI	Flow cytometric immunophenotyping.

Policy Summary

Payermedical mutual - ohio

PolicyFlow Cytometry

Policy CodePolicy AHS - F2019 - Flow Cytometry, 1

Change TypeReviewed and updated (background/guidelines/references)

Effective DateNov 16, 2015

Next Review Date

Key ActionLimit subsequent flow cytometry testing in neoplasms with established immunophenotype to diagnostically relevant markers and document rationale for additional markers.

On This Page

OpenPayer

Flow Cytometry

Coverage Summary

Medical-Necessity / Covered Indications

Not Medically Necessary / Not Covered

Reimbursement / Billing Limitations

Provider Actions & Billing Rules

Background & Evidence Summary

Definitions

Revision History